• Diclofenac

  (Cataflam® Oral; Solaraze™ Topical; Voltaren® Ophthalmic; Voltaren® Oral; Voltaren®-XR Oral)

• Diflunisal

  (Dolobid®)

• Etodolac

  (Lodine®; Lodine® XL)

• Fenoprofen

  (Nalfon®)

• Ibuprofen

  (Advil® Migraine Liqui-Gels [OTC]; Advil®[OTC]; Children's Advil® Oral Suspension [OTC]; Children's Motrin® Oral Suspension [OTC]; Genpril®[OTC]; Haltran®[OTC]; Junior Strength Motrin®[OTC]; Menadol®[OTC]; Midol® IB [OTC]; Motrin®; Motrin® IB [OTC]; Motrin® Migraine Pain [OTC]; Nuprin®[OTC])

• Indomethacin

  (Indocin®)

• Ketoprofen

  (Actron®[OTC]; Orudis®; Orudis® KT [OTC]; Oruvail®)

• Ketorolac Tromethamine

  (Acular® Ophthalmic; Toradol® Injection; Toradol® Oral)

• Meclofenamate

  (Meclomen®)

• Nabumetone

  (Relafen®)

• Naproxen

  (Aleve®[OTC]; Anaprox®; EC Naprosyn®; Naprelan®; Naprosyn®)

• Oxaprozin

  (Daypro™)

• Piroxicam

  (Feldene®)

• Sulindac

  (Clinoril®)

• Tolmetin

  (Tolectin®; Tolectin® DS)

Depleted levels of iron may lead to anemia and weakened immune function. In the event of anemia, symptoms include dizziness, fatigue, shortness of breath, pale skin color, and possibly irregular heartbeat.

Reduced levels of melatonin in the body have been associated with sleep disturbances and jet lag.

Low levels of folic acid have been linked to anemia, heart disease, and birth defects.

Signs and symptoms of zinc deficiency include loss of appetite or sense of taste, growth retardation, skin changes, and increased susceptibility to infection.

Ames BN. Micronutrient deficiencies: A major cause of DNA damage. Ann NY Acad Sci. 2000;889:87-106.

Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrin Metab. 1985;60:1166-1173.

Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Ann Med. 1998;30:122-130.

Baggott, JE, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem. J. 282(Pt.I):197-202, 1992.

Balogh Z, El-Ghobarey AF, Fell GS, et al. Plasma zinc and its relationship to clinical symptoms and drug treatment in rheumatoid arthritis. Ann Rheum Dis. 1980;39:329-332.

Bertschinger P, Zala GF, Fried M. [Effect of non-steroidal antirheumatic agents on the gastrointestinal tract: clinical aspects and pathophysiology]. Schweiz Med Wochenschr. 1996;126(37):1566-1568.

Bjarnason I, Macpherson AJ. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther. 1994;62(1-2):145-157.

Covington T, ed. Nonprescription Drug Therapy Guiding Patient Self-Care. St. Louis, Mo: Facts and Comparisons; 1999: 467-545.

Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum. 1995;38(12):1311-1321.

Elling H, Kiilerich S, Sabro J, Elling P. Influence of a non-steroid anti-rheumatic drug on serum and urinary zinc in healthy volunteers. Scand J Rheumatol. 1980;9:161-163.

Falchuk KH. Disturbances in Trace Elements. In: Fauci A, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 14^th ed. New York, NY: McGraw-Hill Companies Health Professional Division; 1998:490-491.

Hambidge M. Human zinc deficiency. J Nutr. 2000;130(5S Suppl):1344S-1349S.

Rommell T, Demisch L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm [Gen Sect]. 1994;95:39-48.